In vivo and in vitro neuroprotective effects of Panax ginseng glycoproteins

• Published in: International journal of biological macromolecules Vol. 113; pp. 607 - 615
• Main Authors: Luo, Haoming, Hu, Jingting, Wang, Ying, Chen, Yinghong, Zhu, Difu, Jiang, Ruizhi, Qiu, Zhidong
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.07.2018
• Subjects: Amyloid beta-Peptides - chemistry; Amyloid beta-Peptides - toxicity; Animals; Anti-AD activity; Apoptosis - drug effects; Apoptosis - radiation effects; Cell Cycle - drug effects; Cell Cycle - radiation effects; Cell Line, Tumor; Cell Survival - drug effects; Cell Survival - radiation effects; Female; Glycoproteins; Glycoproteins - pharmacology; Humans; Male; Memory - drug effects; Memory - radiation effects; Neuroprotective Agents - pharmacology; Nitric Oxide - secretion; Nitric Oxide Synthase - secretion; Panax - chemistry; Panax ginseng; Peptide Fragments - chemistry; Peptide Fragments - toxicity; Protein Aggregates; Rats; Rats, Wistar; Anti-AD activity; Panax ginseng; Glycoproteins
• ISSN: 0141-8130; 1879-0003
• DOI: 10.1016/j.ijbiomac.2018.02.015

The root of Panax ginseng C. A. Mey (Araliaceae) has medicinal value in complex system of Traditional Chinese medicines for its use in improving cognitive function. A glycoproteins named PGL-1 was extracted from ginseng which subjected to through a macroporous resin, hollow-fiber ultrafiltration and dialyzed. The glycoproteins has a molecular weight in the range from 0.4 to 4.4kDa, with an average molecular mass of 1.6kDa. HPLC analysis revealed that the compositions of glycoproteins included fucose, mannose, rhamnose, glucose, galacturonic acid, N-acetylglucosamine and N-acetylgalactosamine. Glycan of PGL-1 has a backbone of →4)-Rha-(1→, →4)-Fuc -(1→, →6)-Gal-(1→, →4)-GalA-(1→, →4)-GlcNAc-(1→ and →4)-GalNAc-(1→,and (→3,6)-Man-(1→) was distributed in branches. The (1→)-Fuc, (1→)-Glc and (1→)-GlcNAc or (1→)-GalNAc were regarded as a terminal residue. The Morris water maze test revealed that the PGL-1 can effectively alleviate the memory impairment symptoms of rats induced by Aβ25–35. All dose groups showed significant activity of protective effect on apoptosis SH-SY5Y induced by Aβ25–35, and obviously inhibited the S phase arrest. Compared with Aβ25–35 treatment alone, a significant reduction in NO concentration and NOS activity was detected in cells co-administered with glycoproteins. Thus, glycoproteins derived from ginseng might be a promising anti-AD reagent.